Photo via TIME

Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results

Read the original at TIME ↗
Cite

Park, A. (2026, September 29). Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results. TIME. https://time.com/article/2026/09/29/eli-lilly-triple-targeting-experimental-weight-loss-drug-promising-results/

Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.

TIME · collected 2026-09-29 · by Alice Park

Quick Summary

Eli Lilly’s experimental weight-loss drug, retatrutide, showed significant effectiveness in two studies published in The Lancet and the New England Journal of Medicine. Participants with Type 2 diabetes who took the highest dose lost an average of 18.8% of their body weight over a year and a half, compared to 5.1% for those on placebo. In a separate study focusing on overweight or obese individuals without diabetes, retatrutide led to a 25% weight loss in participants versus 3.9% for the placebo group. The drug’s unique mechanism of targeting three hormones—GLP-1, GIP, and glucagon—appears to offer greater benefits compared to existing medications, including improvements in diabetes control and reduced symptoms of osteoarthritis and sleep apnea.
Written by AI on 2026-09-29, from this article's own text only (the story summary below draws on all the coverage).
See how they differ ↓

AI analysis

Story summary

Eli Lilly's experimental drug retatrutide showed promising results for weight loss among people with Type 2 diabetes, according to studies published in The Lancet and New England Journal of Medicine. In one trial, participants taking the highest dose lost an average of 18.8% of their starting body weight over 1.5 years, compared to just 5.1% for those on placebo. Some patients lost up to 60 pounds (23%) of their initial weight, marking it as the most potent drug tested in diabetes care so far. Additionally, retatrutide not only aids significant weight loss but also improves blood sugar control; about 63% of participants lowered their A1C levels below 6.5%, which is indicative of better diabetes management. The drug's unique mechanism—targeting three hormone pathways instead of one or two—may contribute to its effectiveness compared to other GLP-1 drugs like Ozempic and Wegovy (semaglutide), as well as Mounjaro (tirzepatide).

Written for “Lilly Weight Loss Drug Trials” on 2026-11-20, grounded in this article and the 2 other(s) covering the same event.

How they differ

3 outlets covered “Lilly Weight Loss Drug Trials”.

What each outlet says

One AI summary per outlet of its latest article on this story, written from that article alone and checked against it. Open the article for the outlet's own words.

TimeThis outlet29 Sep

Eli Lilly’s experimental weight-loss drug, retatrutide, showed significant effectiveness in two studies published in The Lancet and the New England Journal of Medicine. Participants with Type 2 diabetes who took the highest dose lost an average of 18.8% of their body weight over a year and a half, compared to 5.1% for those on placebo. In a separate study focusing on overweight or obese individuals without diabetes…

Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results (this article)
NBC News29 Sep

Eli Lilly's GLP-1 drug retatrutide helped people with Type 2 diabetes lose up to 60 pounds, or about 23% of their body weight, according to a late-stage trial published in The Lancet. This result is the highest recorded weight loss for a diabetes medication and compares favorably to semaglutide and tirzepatide, which resulted in up to 10% and 15% weight loss respectively. Dr. Susan Spratt of Duke Health highlighted…

People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug →
Daily Mail30 Sep

A new drug called Retatrutide, nicknamed the 'Godzilla' fat jab or 'Reta', is showing promising results in clinical trials for weight loss among obese patients with type 2 diabetes. In a phase 3 trial involving 1,152 participants from eight countries, those on the highest dose of Retatrutide lost up to a quarter of their body weight over 18 months, compared to around 20% for Mounjaro over a similar period. The drug…

'Godzilla' fat jab retatrutide sheds more fat than Mounjaro, new study finds - here's when you can get it in Britain →

Where they agree and split

Framing

How the first headlines put it

Stated as fact3
The headlines (3)

Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results Time · stated as fact

People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug NBC News · stated as fact

'Godzilla' fat jab retatrutide sheds more fat than Mounjaro, new study finds - here's when you can get it in Britain Daily Mail · stated as fact

The full story: what happened, how it changed, and all 3 articles →

Compared with similar articles

This article reads unscored and hedges 7% of its claims. Each row says how that neighbour differs.
NBC News
Hedges 7 of 34 claims Outlet record 78/100
New York Post
Hedges 2 of 25 claims Outlet record 66/100
“The articles discuss different drugs and their effects; one focuses on Eli Lilly's experimental retatrutide while the other discusses GLP-1 medications like Ozempic, Wegovy, and Mounjaro.”
Fox News
Hedges 3 of 23 claims Outlet record 67/100
“The articles discuss different aspects of weight-loss drugs: one warns about high-dose risks and potential health benefits, while the other reports on promising results from an experimental drug by Eli Lilly.”
Daily Mail
Hedges 3 of 41 claims Outlet record 69/100
“The articles discuss different weight-loss drugs and their effects, with Article A focusing on Mysimba and Article B discussing an experimental drug by Eli Lilly.”
New York Post
Hedges 4 of 25 claims Outlet record 66/100
“The articles discuss different drugs and their effects, though both are related to weight-loss treatments.”
New York Post
Hedges 0 of 23 claims Outlet record 66/100
“While both articles discuss Eli Lilly's experimental drug retatrutide for weight loss, they describe different studies or phases of research.”

Story

Lilly Weight Loss Drug Trials
Health · 3 article(s) covering the same event. Compare every outlet's account →
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
15
sentences that state something as happening or true
Uncertain
7%
1 of 15 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
60/100
TIME's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
3
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-09-29 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

TIME · 1067 article(s) · 2 correction(s) detected
Running correction rate · 2 correction(s)

Who wrote this

Alice Park
9 article(s) here · 1 carrying a prediction
A calculation that takes into account a person’s weight and height, BMI is supposed to reflect how much excess fat a person might be carrying and give doctors a sense of a patient's risk for obesity-related health conditions.
2026-11-13 · assertive framing · Why BMI Is Not the Best Measure of Health
Asundexian, which will be sold under the brand name Sunharbo, is a daily pill that is the first to target a specific factor in the blood-clotting process that can contribute to stroke.
On a crisp October day, the CEO of Moderna, of COVID-vaccine fame, is sitting in his glass-walled office in the company’s headquarters in Cambridge, Mass., weeks before encouraging results from the company’s first mRNA cancer vaccine would become public.
2026-11-12 · assertive framing · The Next Chapter of mRNA
The results will be presented at the European Society of Medical Oncology meeting in Madrid on Oct. 24.
Immune-based treatments for cancer have become the biggest new advance in tackling tumors, and the latest approval could make a big difference for some people with rectal cancer.
The scientists used a modified version of a reprogramming strategy that earned a Nobel Prize in 2012 for turning mature, adult cells back to an embryonic-like state from which they could become any of the cells in the body—including healthy new versions of diseased or older cells.
Since each has specific receptors in the body and brain, targeting all three may be contributing to the more potent effects on weight for people with diabetes than drugs that target GLP-1 alone, like Ozempic and Wegovy (semaglutide), or GLP-1 and GIP together, as Mounjaro and Zepbound (tirzepatide) do.
In a new study published in Science, researchers report that for some of those cases, an inherited genetic mutation might be involved.
Also by Alice Park
The Next Chapter of mRNA
2026-11-12 · TIME
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 9 articles by Alice Park →

Topics

Eli Lilly Lancet Ozempic Wegovy Zepbound

Subjects

Eli Lilly ORG · 2× Lancet ORG · 2× Juan Pablo Frias PERSON · 1× the European Association for the Study of Diabetes ORG · 1× the Los Angeles Institute for Metabolic Research ORG · 1× the New England Journal of Medicine ORG · 1× the U.S. Food and Drug Administration ORG · 1×

Narrative

“This is the most potent drug, showing the greatest percent weight loss in people with Type 2 diabetes with a pharmacological agent, shown to date,” says Dr. Juan Pablo Frias, medical director at the Los Angeles Institute for Metabolic Research and one of the Lancet study authors.
framing: assertive · carried by 1 article(s) · first seen 2026-09-29
Since each has specific receptors in the body and brain, targeting all three may be contributing to the more potent effects on weight for people with diabetes than drugs that target GLP-1 alone, like Ozempic and Wegovy (semaglutide), or GLP-1 and GIP together, as Mounjaro and Zepbound (tirzepatide) do.

Claims (15 extracted, 1 hedged)

Two new studies published in separate journals show that an experimental drug developed by Eli Lilly leads to meaningful weight loss. asserted
drug → publish → loss
One study, published in the Lancet and presented at the European Association for the Study of Diabetes, tested the drug retatrutide in people who were overweight or obese and had Type 2 diabetes: a population in which weight-loss medications have historically been less effective. asserted
medications → publish → which
People who took the highest dose lost about 18.8% of their starting body weight, while people who took a placebo lost 5.1%. asserted
who → take → %
About a third of the people in the study who took the highest dose of retatrutide lost at least 25% of their body weight, compared to 3% of those on placebo over the study period of 1.5 years. asserted
who → take → years
“This is the most potent drug, showing the greatest percent weight loss in people with Type 2 diabetes with a pharmacological agent, shown to date,” says Dr. Juan Pablo Frias, medical director at the Los Angeles Institute for Metabolic Research and one of the Lancet study authors. asserted
Frias → show → authors
People in the study also showed improvement in their diabetes control. asserted
People → show → control
Of those who took the highest dose, 63% lowered their A1C to less than 6.5%—the threshold for diabetes—and lost at least 10% of their body weight. asserted
% → take → weight
In another study published in the New England Journal of Medicine, researchers reported similar weight-loss benefits in people who were overweight or obese but who did not have diabetes. asserted
who → publish → diabetes
In that study, people who took the highest dose of retatrutide lost about 25% of their starting body weight, while just 3.9% of people who took a placebo did the same. asserted
who → take → same
People taking the drug were also studied for other benefits; those with osteoarthritis in the knee reported lower pain scores than those on placebo, while people with obstructive sleep apnea also reported fewer apnea episodes than those taking placebo. asserted
people → take → placebo
Retatrutide targets three weight-related hormones: GLP-1, GIP, and glucagon. asserted
Retatrutide → target → hormones
Since each has specific receptors in the body and brain, targeting all three may be contributing to the more potent effects on weight for people with diabetes than drugs that target GLP-1 alone, like Ozempic and Wegovy (semaglutide), or GLP-1 and GIP together, as Mounjaro and Zepbound (tirzepatide) do. uncertain
Mounjaro → have → Ozempic
Zepbound is approved to not only control weight but to also treat obstructive sleep apnea, and Wegovy and Ozempic are approved to reduce the risk of heart disease. asserted
Wegovy → approve → disease
In both studies, the side effects among people taking retatrutide were similar to those that have been reported with other GLP-1 medications, including GI issues such as abdominal cramps, nausea, vomiting, and diarrhea. asserted
that → take → cramps
Eli Lilly says it plans to submit a request in early 2027 to the U.S. Food and Drug Administration to approve retatrutide based on these results. asserted
it → say → results
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support